Literature DB >> 30552450

[Stereotactic body radiation therapy is superior to sorafenib in terms of survival in patients with hepatocellular carcinoma].

Ping Jiang1, Jürgen Dunst2.   

Abstract

Entities:  

Year:  2019        PMID： 30552450     DOI： 10.1007/s00066-018-1408-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.

Authors:  Haoming Qiu; Michael J Moravan; Michael T Milano; Kenneth Y Usuki; Alan W Katz
Journal:  J Gastrointest Cancer       Date:  2018-12

2.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.

Authors:  Alexis Bujold; Christine A Massey; John J Kim; James Brierley; Charles Cho; Rebecca K S Wong; Rob E Dinniwell; Zahra Kassam; Jolie Ringash; Bernard Cummings; Jenna Sykes; Morris Sherman; Jennifer J Knox; Laura A Dawson
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

3.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

4.  Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma.

Authors:  Eli Sapir; Yebin Tao; Matthew J Schipper; Latifa Bazzi; Paula M Novelli; Pauline Devlin; Dawn Owen; Kyle C Cuneo; Theodore S Lawrence; Neehar D Parikh; Mary Feng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-14       Impact factor: 7.038

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Authors:  Valérie Vilgrain; Helena Pereira; Eric Assenat; Boris Guiu; Alina Diana Ilonca; Georges-Philippe Pageaux; Annie Sibert; Mohamed Bouattour; Rachida Lebtahi; Wassim Allaham; Hélène Barraud; Valérie Laurent; Elodie Mathias; Jean-Pierre Bronowicki; Jean-Pierre Tasu; Rémy Perdrisot; Christine Silvain; René Gerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Frédéric Oberti; Olivier Couturier; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sarran; Charlotte Costentin; Emmanuel Itti; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Maxime Ronot; Aurelia Dinut; Laurent Castera; Gilles Chatellier
Journal:  Lancet Oncol       Date:  2017-10-26       Impact factor: 41.316

8.  Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.

Authors:  Mihir Gandhi; Su Pin Choo; Choon Hua Thng; Say Beng Tan; Albert Su Chong Low; Peng Chung Cheow; Anthony Soon Whatt Goh; Kiang Hiong Tay; Richard Hoau Gong Lo; Brian Kim Poh Goh; Jen San Wong; David Chee Eng Ng; Khee Chee Soo; Wei Ming Liew; Pierce K H Chow
Journal:  BMC Cancer       Date:  2016-11-07       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.